

091715,965

Docket No.: 30610/30028A

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Denholm et al.

Patent No.: 6,979,563

Issued: December 27, 2005

For: ATTENUATION OF TUMOR GROWTH,

METASTASIS AND ANGIOGENESIS

REVOCATION AND NEW POWER OF ATTORNEY

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

As the Assignee of the entire right, title, and interest in the abovereferenced patent, all powers previously given are hereby revoked, and all practitioners associated with Customer No. 04743, are hereby appointed to prosecute and transact all business with the United States Patent and Trademark Office in connection with the above application.

The Assignee has reviewed the documentary evidence of the chain of title from the original owner to the Assignee recorded in the U.S. Patent and Trademark Office at Reel/Frame Nos. 012013/0118, 013827/0066 and 017083/0921, and certifies that to the best of its knowledge and belief it is the owner of the entire title, and interest in and to the above-identified patent.

Please direct all further communication and correspondence to Li-Hsien Rin-Laures, M.D., Esq. at the address associated with Customer No. 04743, which is:

MARSHALL, GERSTEIN & BORUN LLP 6300 Sears Tower 233 South Wacker Drive Chicago, Illinois 60606-6357 (312) 474-6300 TELEPHONE (312) 474-0448 FACSIMILE

Signature:

Name:

Title:

PTO/SB/96 (09-06) 03/31/2007. OMB 0651-0031 ARTMENT OF COMMERCE is a valid OMB control number.

IPE	
O. Ag	
JUL 1 6 2007 (2)	
THE STATE OF THE S	Approved for use through 03
TRADENAL THE Paperwork Redu	U.S. Patent and Trademark Office; U.S. DEPAction Act of 1995, no persons are required to respond to a collection of information unless it displays
,	STATEMENT UNDER 37 CFR 3.73(b)

Applicant/Patent Owner: _	BioMarin Pharmaceutical Inc.			
Application No./Patent No.:	6,979,563	Filed/Issue Date:	12/27/2005	
Entitled: Attentuation of Tumor Growth, Metastasis and Angiogenesis				
BioMarin Pharma (Name of Assignee)	ceutical Inc. , a (Type	Corporation of Assignee, e.g., corporation, partnership	on , university, government agency, etc.)	
states that it is:				
1. X the assignee of the	e entire right, title, and interes	st; or		
2. an assignee of less than the entire right, title and interest.				
(The extent (by percentage) of its ownership interest is %)				
in the patent application/patent identified above by virtue of either:				
A. An assignment from the inventor(s) of the patent application/patent identified above. The assignment was recorded in the United States Patent and Trademark Office at Reel, Frame, or a true copy of the original assignment is attached.				
Frame	, or a true copy of the	original assignment is attache	cu.	
B. X A chain of title from the inventor(s), of the patent application/patent identified above, to the current assignee as follows:				
	lm, Lin, & Silver			
	t was recorded in the United S			
Reel <u>012</u>	2013 , Frame 0118	, or for which a copy ther	eof is attached.	
	Pharmaceuticals Inc.		_	
	t was recorded in the United S			
Reel013	3827 , Frame0066	, or for which a copy ther	eoris attached.	
	rin Enzymes Inc.			
	t was recorded in the United S			
Reel011	7083 , Frame <u>0921</u>	, or for which a copy ther	eof is attached.	
Additional documents in the chain of title are listed on a supplemental sheet.				
to the assignee was, of [NOTE: A separate con	R 3.73(b)(1)(i), the documental or concurrently is being, subnoy (i.e., a true copy of the original accordance with 37 CFR Part 3	nitted for recordation pursual al assignment document(s)) mu	nt to 37 CFR 3.11. st be submitted to	
The undersigned (whose title	e is supplied below) is authori	zed to act on behalf of the ass	signee.	
- gate	- Z Ni	Jı	uly 11, 2007	
	Signature		Date	
Katherine L. Neville			12) 474-6300	
	d or Typed Name	I ele	ephone Number	
Authorized	d Signer for Assignee Title			
			· · · · · · · · · · · · · · · · · · ·	